Pacira BioSciences Past Earnings Performance
Past criteria checks 4/6
Pacira BioSciences has been growing earnings at an average annual rate of 1.7%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 14.8% per year. Pacira BioSciences's return on equity is 4.8%, and it has net margins of 6.2%.
Key information
1.7%
Earnings growth rate
1.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 14.8% |
| Return on equity | 4.8% |
| Net Margin | 6.2% |
| Next Earnings Update | 07 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Pacira BioSciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 675 | 42 | 269 | 0 |
| 30 Sep 23 | 666 | 7 | 268 | 0 |
| 30 Jun 23 | 669 | -5 | 261 | 0 |
| 31 Mar 23 | 669 | -10 | 261 | 0 |
| 31 Dec 22 | 667 | 16 | 255 | 0 |
| 30 Sep 22 | 654 | 21 | 243 | 0 |
| 30 Jun 22 | 614 | 39 | 229 | 0 |
| 31 Mar 22 | 580 | 38 | 215 | 0 |
| 31 Dec 21 | 542 | 42 | 199 | 0 |
| 30 Sep 21 | 513 | 62 | 200 | 0 |
| 30 Jun 21 | 503 | 174 | 205 | 0 |
| 31 Mar 21 | 443 | 148 | 197 | 0 |
| 31 Dec 20 | 430 | 146 | 194 | 0 |
| 30 Sep 20 | 421 | 126 | 197 | 0 |
| 30 Jun 20 | 408 | -10 | 195 | 0 |
| 31 Mar 20 | 435 | 0 | 200 | 0 |
| 31 Dec 19 | 421 | -11 | 201 | 0 |
| 30 Sep 19 | 394 | 2 | 191 | 0 |
| 30 Jun 19 | 372 | 8 | 185 | 0 |
| 31 Mar 19 | 354 | 7 | 180 | 0 |
| 31 Dec 18 | 337 | 0 | 177 | 0 |
| 30 Sep 18 | 321 | -4 | 172 | 0 |
| 30 Jun 18 | 305 | -11 | 168 | 0 |
| 31 Mar 18 | 292 | -33 | 164 | 0 |
| 31 Dec 17 | 287 | -43 | 161 | 0 |
| 30 Sep 17 | 280 | -51 | 157 | 0 |
| 30 Jun 17 | 281 | -66 | 153 | 0 |
| 31 Mar 17 | 280 | -54 | 157 | 0 |
| 31 Dec 16 | 276 | -38 | 153 | 0 |
| 30 Sep 16 | 273 | -36 | 155 | 0 |
| 30 Jun 16 | 267 | -11 | 154 | 0 |
| 31 Mar 16 | 256 | -3 | 146 | 0 |
| 31 Dec 15 | 249 | 2 | 139 | 0 |
| 30 Sep 15 | 241 | 10 | 133 | 0 |
| 30 Jun 15 | 231 | 4 | 125 | 0 |
| 31 Mar 15 | 219 | -1 | 116 | 0 |
| 31 Dec 14 | 198 | -14 | 107 | 0 |
| 30 Sep 14 | 169 | -31 | 96 | 0 |
| 30 Jun 14 | 141 | -43 | 83 | 0 |
| 31 Mar 14 | 111 | -52 | 72 | 0 |
| 31 Dec 13 | 86 | -64 | 63 | 22 |
| 30 Sep 13 | 62 | -68 | 56 | 0 |
| 30 Jun 13 | 48 | -69 | 52 | 0 |
Quality Earnings: 82P has a large one-off loss of $16.6M impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: 82P's current net profit margins (6.2%) are higher than last year (2.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 82P has become profitable over the past 5 years, growing earnings by 1.7% per year.
Accelerating Growth: 82P's earnings growth over the past year (163.7%) exceeds its 5-year average (1.7% per year).
Earnings vs Industry: 82P earnings growth over the past year (163.7%) exceeded the Pharmaceuticals industry 2.7%.
Return on Equity
High ROE: 82P's Return on Equity (4.8%) is considered low.